Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Mar;11(1):83-92.
doi: 10.1007/s10741-006-9196-2.

Systemic inflammation in heart failure--the whys and wherefores

Arne Yndestad  1 , Jan Kristian Damås, Erik Oie, Thor Ueland, Lars Gullestad, Pål Aukrust
Affiliations
Review

Systemic inflammation in heart failure--the whys and wherefores

Arne Yndestad et al. Heart Fail Rev. 2006 Mar.

Abstract

Patients with chronic heart failure (HF) are characterized by systemic inflammation, as evident by raised circulating levels of several inflammatory cytokines with increasing levels according to the degree of disease severity. In addition to the myocardium itself, several tissues and cells can contribute to this inflammation, including leukocytes, platelets, tissue macrophages and endothelial cells. Although the mechanisms for the systemic inflammation is unknown, both infectious (e.g., endotoxins) and non-infectious (e.g., oxidative stress and hemodynamic overload) events could be operating, also including activation of Toll-like receptors as well as interaction with the neurohormone system. A growing body of evidence suggests that this systemic inflammation in chronic HF may play a role in the development and progression of this disorder, not only by promoting myocardial dysfunction, but also by inducing pathogenic consequences in other organs and tissues, thereby contributing to additional aspects of the HF syndrome such as cachexia, endothelial dysfunction and anemia. Although this inappropriate immune activation and inflammation could represent a new target for therapy in patients with chronic HF, the anti-tumor necrosis factor trials have been disappointing, and future research in this area will have to more precisely identify the most important mechanisms and actors in the immunopathogenesis of chronic HF in order to develop better immunomodulating agents for this disorder.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. J Am Coll Cardiol. 1999 Dec;34(7):2061-7 - PubMed
    1. J Card Fail. 2004 Feb;10(1 Suppl):S5-9 - PubMed
    1. Cardiovasc Res. 1998 Dec;40(3):426-32 - PubMed
    1. Circulation. 2005 May 17;111(19):2461-8 - PubMed
    1. Lancet. 1999 May 29;353(9167):1838-42 - PubMed

MeSH terms

-